$RXMD is getting more attention and coverage for t
Post# of 43922
(Total Views: 62)
Posted On: 11/30/2020 11:29:35 AM
$RXMD is getting more attention and coverage for the company's increasingly important healthcare business services:
TNS Comprehensive Research on The Hottest OTC Stocks
November 30 2020 - 08:35AM
InvestorsHub NewsWire
https://ih.advfn.com/stock-market/USOTC/progr...t-otc-stoc
From the feature today:
Progressive Care, Inc. (OTCQB: RXMD) a personalized healthcare services and technology company, announced performance data for the three months ended September 30, 2020, including strong topline and bottom line growth, positive EBITDA, increased margins and continued strong cash resources on hand at the close of the quarter.
Consolidated gross sales across all locations during the three months ended September 30, 2020, totaled $10.7 million.
Prescriptions filled during 3rd Quarter were over 138,000.
Margins increased from 24% to 27% during the quarter (on a year over year basis).
Positive EBITDA of $300,000 for the quarter (Non-GAAP Measure).
Cash and cash equivalents stood at $1.6 million as of September 30, 2020; and
The Company’s COVID-19 Testing services continue to expand, with growth in clients accelerating as the number of COVID-19 cases increases in the northern hemisphere and businesses seeking outpatient/on-site services utilize the Company’s 15-minute rapid results testing solution.
TNS Comprehensive Research on The Hottest OTC Stocks
November 30 2020 - 08:35AM
InvestorsHub NewsWire
https://ih.advfn.com/stock-market/USOTC/progr...t-otc-stoc
From the feature today:
Progressive Care, Inc. (OTCQB: RXMD) a personalized healthcare services and technology company, announced performance data for the three months ended September 30, 2020, including strong topline and bottom line growth, positive EBITDA, increased margins and continued strong cash resources on hand at the close of the quarter.
Consolidated gross sales across all locations during the three months ended September 30, 2020, totaled $10.7 million.
Prescriptions filled during 3rd Quarter were over 138,000.
Margins increased from 24% to 27% during the quarter (on a year over year basis).
Positive EBITDA of $300,000 for the quarter (Non-GAAP Measure).
Cash and cash equivalents stood at $1.6 million as of September 30, 2020; and
The Company’s COVID-19 Testing services continue to expand, with growth in clients accelerating as the number of COVID-19 cases increases in the northern hemisphere and businesses seeking outpatient/on-site services utilize the Company’s 15-minute rapid results testing solution.
(0)
(0)